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Abstract
In vivo quantification of b-amyloid deposition using positron emission tomography is emerging as an important procedure
for the early diagnosis of the Alzheimer’s disease and is likely to play an important role in upcoming clinical trials of disease
modifying agents. However, many groups use manually defined regions, which are non-standard across imaging centers.
Analyses often are limited to a handful of regions because of the labor-intensive nature of manual region drawing. In this
study, we developed an automatic image quantification protocol based on FreeSurfer, an automated whole brain
segmentation tool, for quantitative analysis of amyloid images. Standard manual tracing and FreeSurfer-based analyses
were performed in 77 participants including 67 cognitively normal individuals and 10 individuals with early Alzheimer’s
disease. The manual and FreeSurfer approaches yielded nearly identical estimates of amyloid burden (intraclass
correlation = 0.98) as assessed by the mean cortical binding potential. An MRI test-retest study demonstrated excellent
reliability of FreeSurfer based regional amyloid burden measurements. The FreeSurfer-based analysis also revealed that the
majority of cerebral cortical regions accumulate amyloid in parallel, with slope of accumulation being the primary difference
between regions.
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Introduction
The prevalence of Alzheimer’s disease (AD) is expected to
increase dramatically worldwide within the next 50 years [1]. The
future success of disease-modifying therapies will depend on
accurate early diagnosis before the onset of clinical symptoms
[2,3,4]. Amyloid-beta (Ab) plaque deposition is a hallmark of AD
[5,6]. With the development of positron emission tomography
(PET) tracers with high affinity for Ab plaques, such as 11C-
Pittsburgh Compound B (PiB), it is now possible to quantify
neuropathology that was previously detectable only by post-
mortem examination [7]. PET enables in vivo visualization of AD
pathology and allows for a broad range of metabolic processes to
be assessed in preclinical and clinical AD. Individuals with AD and
mild cognitive impairment have been shown to have elevated PiB
retention in the cerebral cortex [7,8,9] although elevated PiB
retention is also observed in some cognitively normal individuals.
Ab deposition in asymptomatic individuals may represent a
preclinical biomarker of AD [10,11]. Therefore, it is critical to
quantify the Ab burden accurately and robustly, to further our
understanding of disease mechanisms and to develop early
diagnostic techniques.
Various imaging protocols and analysis procedures currently
exist for PiB PET imaging. Our approach utilizes a 60-minute
dynamic PiB scan. Binding potentials (BPND) are calculated using
Logan graphical analysis [12] with cerebellar cortex as the
reference region [4,11,13]. Manually defined regions of interest
(ROIs) routinely examined include: prefrontal cortex (PREF),
lateral temporal cortex (TEMP), precuneus (PREC), occipital lobe
(OCC), head of the caudate (CAU), gyrus rectus (GR), cerebellum
(CER), and brainstem (BS), with a predetermined set of rules for
ROI delineation using co-registered MR images [11]. Based on
these ROIs, our laboratory defines the mean cortical binding
potential (MCBP) value as the mean BPND in PREF, PREC,
TEMP, and GR [11]. Other investigators may use a dynamic scan
of 90 minutes with a distribution volume ratio (DVR) value
calculated using cerebellum as the reference region [14,15,16] and
a different selection of manually defined ROIs. Additional
technical variations include, but are not limited to, the use of
standard uptake value ratio [17,18,19] and voxel-wise analyses
[20,21]. Due to the variation in imaging and data analysis
protocols, it is not known whether findings from different research
groups can be meaningfully compared. One key difficulty in
achieving a standard protocol is dependence on manually drawn
regions. One laboratory has reported good inter-rater reliability (in
5 control and 5 AD individuals) [22], but reproducibility was
limited to the same research group. It should also be noted that, in
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many amyloid imaging studies using either hand drawn regions
[11,13,14,15,17,19] or automatic templates [22,23,24], the
rationale for ROI selection typically has been based on which
regions have been previously reported as selectively affected by
AD [11,16,24]. Other regions have generally been overlooked
except in voxel-based analysis [21,25].
This study has three aims. First, we develop an automated,
regional, quantitative amyloid imaging analysis protocol using
FreeSurfer (Martinos Center for Biomedical Imaging, Charles-
town, Massachusetts). We demonstrate that this protocol generates
global amyloid deposition measurements comparable to results
obtained with conventional hand drawn regions. FreeSurfer
automatically segments and parcellates T1-weighted brain MRIs
[26,27,28]. This tool has been used in many neuroimaging studies,
including those focused on AD [29,30,31]. As a second aim, we
examine test-retest reliability of the FreeSurfer based technique by
analyzing the same PiB scan with FreeSurfer segmentation results
from two consecutive MR scans. Finally, we investigate the
distribution of amyloid deposition in FreeSurfer-defined cortical,
subcortical and white matter regions of interest throughout the
brain. Since the start of this work, a few groups has published their
research using FreeSurfer to facilitate PiB imaging quantification
[32,33,34], the relationship of FreeSurfer based quantification to
manual based quantification has not been examined. It is also
unknown how much the uncertainty in FreeSurfer segmentation
would affect PiB quantification. We examine both of these two
questions in this study.
Methods
I. Participants
Seventy-seven individuals (G1) aged 48 to 90 years old were
selected from a larger population enrolled at the Washington
University Knight Alzheimer’s Disease Research Center
(KADRC) in longitudinal studies of memory and aging. This
cohort comprised 49 females and 28 males; 27 individuals were
APOE4+ and 50 individuals were APOE4-. G1 includes
representative participants across age and PiB status. Individuals
were not excluded based on imaging findings; one individual had
encephalomalacia, which provided a useful comparison between
the manual and automated approaches. The clinical assessment
protocol has been previously described [11,35,36]. In brief, a
clinician determines the presence or absence of dementia and rates
the severity in accordance with the Clinical Dementia Rating
(CDR). CDR 0 indicates no cognitive impairment and CDR 0.5,
1, 2 and 3 indicate very mild, mild, moderate and severe dementia
[35]. Our study included 67 non-demented individuals (CDR 0)
and 10 individuals with very mild or mild dementia of the
Alzheimer’s type (CDR 0.5 or 1). All imaging was performed
between 2005 and 2010.
A separate group of forty individuals (G2) aged 46 to 79 years
old were selected from our KADRC participants for an MRI test-
retest study. This cohort consisted of 29 females and 11 males; 15
individuals were APOE4+ and 24 were APOE4-; three individuals
had CDR rating of 0.5; one individual had no APOE status or
CDR rating.
I.1 Ethics statement. All assessment and imaging proce-
dures were approved by Washington University’s Human Studies
Committee. Written informed consent was obtained from all
individuals or their care givers.
II. Imaging
In both cohorts, human brain PET imaging for amyloid
deposition was performed using the radiotracer N-methyl-[11C]2-
(4-methylaminophenyl)-6-hydroxybenzothiazole (PiB). Prepara-
tion of PiB was carried out according to the published protocol
[37]. Dynamic PET imaging was conducted with a Siemens 962
HR+ ECAT scanner in three-dimensional mode after intravenous
administration of approximately 12mCi of PiB. The images were
reconstructed on a 1286128663 matrix (2.1262.1262.43 mm)
using filtered back-projection. Typical dynamic scans had
2565 seconds frames, 9620 seconds frames, 1061 minute
frames, and 965 minutes frames.
For G1, anatomic MRI images were acquired with T1-weighted
magnetization-prepared rapid gradient echo (MPRAGE) sequence
(1 mm isotropic voxels) variably using a Siemens Trio 3T scanner
(N= 72), a Siemens Vision 1.5T (N= 3), or a Siemens Avanto 1.5
T scanner (N= 2). For G2, two MPRAGE scans were acquired
Figure 1. Example of regions-of-interest (ROI) defined manu-
ally on one of individual.
doi:10.1371/journal.pone.0073377.g001
Table 1. Manual ROIs and their FreeSurfer counterpart.
Manual
ROI FreeSurfer ROI Dice Coefficient
CAU Caudate 0.32
CER Cerebellum-Cortex 0.15
GR ctx-lateralorbitofrontal 0.14 0.20
(combined)
ctx-medialorbitofrontal 0.15









TEMP ctx-superiortemporal 0.13 0.18
(combined)
ctx-middletemporal 0.11
CAU= caudate; CER = cerebellum; GR = gyrus rectus; OCC= occipital cortex;
PAR= parietal cortex; PREC = precuneus; PREF = prefrontal cortex; RAC = rostral
anterior cingulate; TEMP= lateral temporal cortex. FreeSurfer ROI lists the
combined FreeSurfer left and right region.
doi:10.1371/journal.pone.0073377.t001
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during the same MR session for each participant on the Siemens
Trio 3T scanner to investigate the impact of FreeSurfer
segmentation variability on PET quantification.
III. Manual ROI analysis
ROIs (Fig. 1) were manually defined according to previously
described rules [11] using ANALYZETM software [38] and MRI
images previously transformed (12-parameter affine) to atlas space
[39]. These regions were originally selected through review of the
30 to 60 minute PiB PET images in Alzheimer individuals to
optimize the detection of elevated PiB uptake [11]. PET-MR
registration was performed using the VGM algorithm [40].
Manually defined ROIs were then transformed to the native
PET space. Inter-frame motion correction for the dynamic PET
images was performed using standard image registration tech-
niques [41] implemented in in-house software [39]. Regional time-
activity curves for each ROI were extracted by resampling the
ROIs on the co-registered, unblurred PET images. Regional
binding potentials (BPND) were estimated using Logan graphical
analysis [12] with cerebellar cortex as reference [42]. The average
of BPND from four regions (PREF, PREC, GR, and TEMP)
determined the mean cortical binding potential (MCBP) [11]. The
washout rate constant (k2) of the reference region (cerebellum) was
set to 0.16/minute. It has previously been shown that varying k2
over a 10-fold range (0.05 to 0.5/minute) has minimal impact on
the BPND values [11].
IV. FreeSurfer based analysis
FreeSurfer 5.0 was used to automatically segment the brain into
various regions for G1 (as defined in the wmparc.mgz file);
FreeSurfer 5.1 was used for brain segmentation for G2. Visual
inspection of the automated segmentation results was performed
for quality assurance purposes in all datasets. Correction was done
when necessary according to the FreeSurfer manual (http://surfer.
nmr.mgh.harvard.edu/fswiki/). Corresponding regions from the
left and right hemispheres of the brain were combined to form a
single ROI, e.g., the Left-Cerebellum-Cortex and the Right-
Cerebellum-Cortex were combined to form a single ROI for
quantitative analysis. The procedures used to compute BPND
values from FreeSurfer-defined and manually traced ROIs were
otherwise identical.
To generate a comparable global amyloid deposition index
similar to MCBP from our manual region approach, volumetric
analysis was performed to identify FreeSurfer cortical regions
maximally overlapping the manual ROIs (Table 1). To estimate
the FreeSurfer version of MCBP (MCBP_FS), the FreeSurfer
counterparts of the four manual regions (PREC_FS, PREF_FS,
GR_FS, TEMP_FS) for MCBP calculation were used in the same
fashion as in the manual technique.
V. Partial volume correction
In addition to analysis based on raw regional time-activity
curves, partial volume corrected results were also obtained for G1
using a two-component technique [43] that has been widely
applied in the context of PiB data analysis [14,16,17]. A brain
tissue mask is generated based on FreeSurfer segmentation, a CSF
dilution factor is calculated for each region, and the raw time-
activity curve for each region is corrected by this dilution factor
before BPND is calculated.
VI. Test-retest study (G2)
For G2, we processed the same PiB dataset with FreeSurfer
ROIs generated based on the two different MPRAGE scans. A
mean test-retest variability measurement DBP% was calculated for









where, N is the total number of participants (40), i is the index for
individual patients, BPNDi1 and BPNDi2 are the estimated BPND
using the first and second MPRAGE, respectively. In addition, a
volumetric variability measurement DVOL% was also calculated
for each region based on the repeated MPRAGE and FreeSurfer









where, VOLi1 and VOLi2 are the total number of voxels in each
FreeSurfer region obtained with the first and second MPRAGE.
VII. Statistical analysis
Intra-class correlation coefficients (ICC) were calculated to
examine the agreement between binding potentials estimated
using the manual and FreeSurfer approaches. SAS software (SAS
Institute Inc., Cary, North Carolina, USA) was used to calculate
the ICC estimates and their confidence intervals. We adjusted for
CDR status (CDR=0: negative, CDR.0: positive), age, and
ApoE4 status. ApoE4 status was defined as 0 (no copies ApoE4) or
1 (at least 1 copy of the ApoE4 allele). To adjust for these
covariates, mixed models with a variance components structure
were employed to estimate the ICC and 95% confidence intervals.
We specified a random intercept to account for the within-subject
correlation caused by each subject having two regional binding
potential observations. In addition, we treated rater as a random
effect. The variance components estimated from the mixed model






2), where s2w is the within-subject variance, s
2
r is
the within-rater variance, and s2 is the residual variance.
In the MRI test-retest study, in addition to test-retest variability
as defined by Eqs. 1 and 2, ICC was also calculated for repeated
measurements of BPND and FreeSurfer regional volumes for
comparison with previously reported results.
To examine regional amyloid binding patterns, the Pearson
correlation coefficient was evaluated across subjects between the
Figure 2. Scatter plot of MCBP values obtained using manually
and FreeSurfer defined ROIs (previously shown in [47]).
doi:10.1371/journal.pone.0073377.g002
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Table 2. Test-retest reliability of FreeSurfer based PiB quantification in G2.
ROI DBP% DVOL% ICC_BP (95% CI) ICC_VOL (95% CI)
Cerebellum-White-Matter 0.71 3.88 0.978(0.958;0.988) 0.920(0.855;0.957)
Thalamus-Proper 0.68 3.06 0.990(0.981;0.995) 0.930(0.871;0.962)
Caudate 0.44 1.66 0.999(0.999;1.000) 0.987(0.975;0.993)
Putamen 0.26 2.38 1.000(0.999;1.000) 0.965(0.935;0.981)
Pallidum 0.86 4.91 0.981(0.965;0.990) 0.847(0.730;0.916)
Hippocampus 0.28 1.67 0.998(0.997;0.999) 0.983(0.968;0.991)
Amygdala 0.65 3.41 0.994(0.988;0.997) 0.959(0.920;0.979)
Accumbens-area 1.12 7.51 0.997(0.995;0.999) 0.854(0.741;0.920)
VentralDC 0.42 2.36 0.995(0.990;0.997) 0.931(0.873;0.963)
choroid-plexus 1.03 4.96 0.993(0.986;0.996) 0.959(0.923;0.978)
Brain-Stem 0.34 1.12 0.996(0.993;0.998) 0.989(0.980;0.994)
CC_Posterior 0.99 1.55 0.988(0.977;0.994) 0.994(0.988;0.997)
CC_Mid_Posterior 1.91 2.81 0.985(0.972;0.992) 0.987(0.976;0.993)
CC_Central 1.83 3.58 0.970(0.944;0.984) 0.954(0.916;0.976)
CC_Mid_Anterior 1.29 2.12 0.995(0.990;0.997) 0.986(0.974;0.993)
CC_Anterior 0.71 1.94 0.993(0.986;0.996) 0.991(0.984;0.995)
ctx-bankssts 0.63 4.59 0.999(0.998;0.999) 0.911(0.838;0.952)
ctx-caudalanteriorcingulate 0.43 3.49 0.999(0.999;1.000) 0.982(0.966;0.990)
ctx-caudalmiddlefrontal 0.53 3.46 0.999(0.999;1.000) 0.980(0.962;0.989)
ctx-cuneus 0.53 3.52 0.997(0.993;0.998) 0.919(0.853;0.956)
ctx-entorhinal 1.21 6.34 0.979(0.961;0.989) 0.927(0.866;0.960)
ctx-fusiform 0.40 2.54 0.999(0.998;0.999) 0.973(0.949;0.986)
ctx-inferiorparietal 0.51 2.21 0.999(0.999;1.000) 0.971(0.946;0.984)
ctx-inferiortemporal 0.54 2.54 0.999(0.998;1.000) 0.971(0.946;0.985)
ctx-isthmuscingulate 0.56 2.88 0.999(0.998;0.999) 0.951(0.910;0.974)
ctx-lateraloccipital 0.55 2.08 0.997(0.995;0.999) 0.973(0.949;0.985)
ctx-lateralorbitofrontal 0.45 2.43 0.999(0.999;1.000) 0.953(0.911;0.975)
ctx-lingual 0.37 1.78 0.998(0.996;0.999) 0.988(0.978;0.994)
ctx-medialorbitofrontal 0.69 3.13 0.999(0.998;1.000) 0.925(0.864;0.960)
ctx-middletemporal 0.47 2.26 0.999(0.999;1.000) 0.962(0.928;0.980)
ctx-parahippocampal 0.51 3.32 0.997(0.995;0.998) 0.938(0.887;0.967)
ctx-paracentral 0.46 3.64 0.999(0.998;1.000) 0.948(0.905;0.972)
ctx-parsopercularis 0.43 2.33 1.000(0.999;1.000) 0.982(0.966;0.990)
ctx-parsorbitalis 0.71 2.68 0.999(0.999;1.000) 0.954(0.915;0.975)
ctx-parstriangularis 0.56 3.07 0.999(0.999;1.000) 0.966(0.936;0.982)
ctx-pericalcarine 0.46 3.99 0.998(0.996;0.999) 0.941(0.891;0.968)
ctx-postcentral 0.45 3.53 0.999(0.998;0.999) 0.939(0.888;0.967)
ctx-posteriorcingulate 0.39 2.61 1.000(1.000;1.000) 0.970(0.945;0.984)
ctx-precentral 0.35 3.67 0.999(0.998;1.000) 0.910(0.837;0.952)
ctx-precuneus 0.31 2.11 0.999(0.999;1.000) 0.973(0.951;0.986)
ctx-rostralanteriorcingulate 0.53 3.50 1.000(0.999;1.000) 0.978(0.958;0.988)
ctx-rostralmiddlefrontal 0.45 2.09 1.000(0.999;1.000) 0.978(0.958;0.988)
ctx-superiorfrontal 0.34 2.00 1.000(1.000;1.000) 0.966(0.936;0.982)
ctx-superiorparietal 0.41 2.29 0.999(0.999;1.000) 0.973(0.949;0.985)
ctx-superiortemporal 0.33 1.50 1.000(0.999;1.000) 0.984(0.968;0.992)
ctx-supramarginal 0.33 2.54 1.000(0.999;1.000) 0.961(0.928;0.979)
ctx-frontalpole 1.65 8.76 0.995(0.990;0.997) 0.684(0.476;0.820)
ctx-temporalpole 1.45 6.03 0.988(0.978;0.994) 0.811(0.670;0.896)
ctx-transversetemporal 0.46 4.93 0.999(0.998;0.999) 0.920(0.854;0.957)
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regional BPND and the MCBP. Pearson correlation was also
evaluated between cortical gray matter regions and the underlying
white matter regions. Both Pearson correlation and Spearman
correlation were evaluated for BPND estimated with and without
partial volume correction.
We have previously used a manual MCBP cutoff of 0.18 as the
criterion for PiB status determination [11,44,45]. To investigate
the impact of using the FreeSurfer-based PiB quantification
technique to assess PiB status, we also examined the feasibility of
Table 3. Correlations of binding potentials between raw
measurements and partial volume corrected measurements






Cerebellum-White-Matter 0.544 0.012 0.798 0.747
Thalamus-Proper 0.862 20.037 0.958 0.917
Caudate 0.985 0.037 0.980 0.934
Putamen 0.826 20.134 0.989 0.958
Pallidum 0.744 20.093 0.948 0.933
Hippocampus 0.506 20.008 0.539 0.543
Amygdala 0.995 20.051 0.872 0.875
Accumbens-area 0.953 20.065 0.993 0.976
VentralDC 0.856 0.030 0.939 0.927
Brain-Stem 0.932 0.036 0.926 0.877
ctx-cuneus 0.925 0.176 0.878 0.800
ctx-inferiorparietal 1.187 0.142 0.993 0.929
ctx-lateralorbitofrontal 1.191 0.144 0.993 0.961
ctx-lingual 1.014 0.095 0.929 0.825
ctx-medialorbitofrontal 1.223 0.175 0.993 0.950
ctx-middletemporal 1.213 0.144 0.992 0.938
ctx-precuneus 1.138 0.089 0.990 0.940
ctx-rostralanteriorcingulate 1.124 0.133 0.981 0.881
ctx-rostralmiddlefrontal 1.240 0.219 0.994 0.944
ctx-superiorfrontal 1.218 0.183 0.992 0.915
ctx-superiortemporal 1.240 0.160 0.985 0.882
MCBP 1.202 0.142 0.995 0.955
Also listed were the slope and intercept of the linear fitting between raw
measurements and partial volume corrected ones. All the correlations were




ROI DBP% DVOL% ICC_BP (95% CI) ICC_VOL (95% CI)
ctx-insula 0.32 3.01 1.000(0.999;1.000) 0.939(0.889;0.967)
UnsegmentedWhiteMatter 0.29 1.32 0.998(0.996;0.999) 0.996(0.993;0.998)
GR_FS 0.47 1.85 0.999(0.999;1.000) 0.970(0.944;0.984)
TEMP_FS 0.34 1.73 1.000(0.999;1.000) 0.975(0.951;0.987)
OCC_FS 0.37 1.92 0.998(0.996;0.999) 0.977(0.958;0.988)
PREF_FS 0.35 1.84 1.000(1.000;1.000) 0.976(0.955;0.987)
MCBP 0.25 1.27 1.000(1.000;1.000) 0.983(0.968;0.991)
doi:10.1371/journal.pone.0073377.t002
Table 4. Correlations of cortical regions binding potentials to
MCBP and to their corresponding white matter regions in G1.
Structure MCBP white matter
r slope intercept r
ctx-rostralmiddlefrontal 0.984 1.227 20.061 0.966
ctx-medialorbitofrontal 0.980 1.077 20.028 0.965
ctx-precuneus 0.980 1.161 0.058 0.937
ctx-superiorfrontal 0.978 0.963 20.032 0.940
ctx-lateralorbitofrontal 0.978 0.897 0.018 0.932
ctx-caudalmiddlefrontal 0.976 0.897 0.011 0.872
ctx-parstriangularis 0.976 0.934 0.030 0.937
ctx-parsorbitalis 0.973 1.019 20.054 0.975
ctx-superiortemporal 0.968 0.737 20.010 0.951
ctx-parsopercularis 0.966 0.903 0.024 0.926
ctx-supramarginal 0.966 0.880 20.005 0.924
ctx-middletemporal 0.961 0.862 20.018 0.964
ctx-posteriorcingulate 0.960 0.969 0.046 0.701
ctx-inferiorparietal 0.960 0.946 20.003 0.953
ctx-rostralanteriorcingulate 0.955 1.132 0.015 0.846
ctx-caudalanteriorcingulate 0.951 0.960 0.033 0.686
ctx-superiorparietal 0.944 0.753 20.032 0.933
ctx-inferiortemporal 0.942 0.774 20.004 0.935
ctx-insula 0.938 0.651 0.019 0.808
ctx-bankssts 0.935 0.986 0.141 0.905
ctx-postcentral 0.919 0.535 20.037 0.946
ctx-fusiform 0.914 0.551 0.049 0.882
ctx-precentral 0.911 0.475 0.038 0.807
ctx-paracentral 0.892 0.644 0.058 0.803
ctx-isthmuscingulate 0.884 0.757 0.065 0.650
ctx-transversetemporal 0.866 0.561 0.085 0.908
ctx-parahippocampal 0.859 0.400 20.031 0.853
ctx-temporalpole 0.856 0.373 20.109 0.872
ctx-lateraloccipital 0.772 0.436 20.002 0.911
ctx-lingual 0.749 0.305 0.068 0.902
ctx-pericalcarine 0.742 0.437 0.103 0.880
ctx-cuneus 0.652 0.295 0.103 0.866
ctx-entorhinal 0.583 0.173 20.025 0.680
All the correlations were statistically significant (p,1026), correction for
multiple comparison was not performed.
doi:10.1371/journal.pone.0073377.t004
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classifying participants as either PiB- or PiB+ using FreeSurfer-
based global or regional binding potentials. These classifications
were compared with results obtained by the manual MCBP
approach.
VIII. Software
The FreeSurfer-based analysis workflow has been implemented
as an open source package that can be run from a linux command
line or through the XNAT imaging informatics platform [46].
Specific modules include PET quantification and partial volume
correction (C source code), a toolbox for image registration and
analysis (C and Fortran), and a Unix shell script for executing the
full workflow. The source code for the partial volume correction is
available at (https://bitbucket.org/nrg/fs_tools). The XNAT
module includes: a pipeline for executing the workflow, data
types for representing the FreeSurfer and MCBP output, and web-
based reports for displaying quality control and data reports. The
XNAT module can be accessed on the XNAT Marketplace at
https://marketplace.xnat.org/fspet.
Results
I. Manual vs. FreeSurfer region definitions
Excellent agreement in MCBP measurement was observed
between the manual and FreeSurfer based approaches without
partial volume correction (ICC=0.98 (95%CI: 0.97, 0.99)) (A
recent review (in Russian) [47] briefly mentioned our technique
and a modified version of Figure 2 was shown to demonstrate
the FreeSurfer based quantification method as an effective
approach for routine analysis of amyloid PET imaging data).
The results obtained by both methods were highly
correlated (Pearson r = 0.99, p,10268, MCBP_FS=0.916
MCBP_MAN+0.03; Spearman r= 0.94). These results were
generated without considering the MR scanner differences. The
same outcome was obtained controlling for variability in MR
scanners and excluding the 5 subjects scanned at 1.5T. Therefore,
all the analyses presented below were based on all the participants
without controlling for MR scanner differences. When partial
volume correction was applied, agreement was still excellent
although ICC decreased slightly (ICC=0.95, 95%CI: 0.94, 0.96).
With partial volume correction, the Pearson correlation between
the two approaches was 0.99 (p,10268), and Spearman correla-
tion was 0.92.
To categorize subjects as PiB- vs. PiB+, a MCBP cutoff value of
0.18 has been used in previous studies [11,44,45]. Using the same
cutoff, the present cohort was separated into 52 PiB- subjects and
Table 5. Correlation of binding potentials to MCBP for
subcortical structures (G1).
Structure r p-value slope intercept
Cerebellum-White-Matter 20.252 0.027 20.082 0.377
Thalamus-Proper 0.512 0.000002 0.204 0.359
Caudate 0.853 ,1026 0.687 20.008
Putamen 0.862 ,1026 0.634 0.253
Pallidum 0.396 0.0004 0.162 0.440
Hippocampus 0.152 0.186 0.036 0.074
Amygdala 0.466 0.00002 0.151 0.095
Accumbens-area 0.913 ,1026 0.924 0.014
Substancia-Nigra 0.144 0.211 0.093 0.072
VentralDC 20.054 0.639 20.019 0.377
choroid-plexus 20.189 0.100 20.084 20.193
Brain-Stem 20.242 0.034 20.075 0.437
CC_Posterior 20.046 0.691 20.031 0.310
CC_Mid_Posterior 20.031 0.786 20.024 20.043
CC_Central 20.088 0.448 20.068 20.037
CC_Mid_Anterior 20.008 0.948 20.005 20.019
CC_Anterior 0.019 0.872 0.013 0.202
doi:10.1371/journal.pone.0073377.t005
Figure 3. Correlation of regional binding potential and MCBP
for selected regions.
doi:10.1371/journal.pone.0073377.g003
Figure 4. Average regional amyloid deposition for the CDR0
group (top row) and the CDR+ group (bottom row) quantified
using FreeSurfer regions. For each group the lateral (left) and
medial (right) surfaces of the left hemisphere were illustrated.
doi:10.1371/journal.pone.0073377.g004
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25 PiB+ subjects based on the conventional manual approach.
Determination of PiB status was identical using FreeSurfer ROIs
and the same 0.18 cutoff, which further demonstrates the
equivalence of the two approaches.
II. MRI Test-retest reproducibility
Test-retest data are listed in Table 2. FreeSurfer segmented
ROI volumes varied by a few percent (nominally, ,5%) on repeat
MRI. ICC values for ROI volume ranged from 0.684 for the
frontal pole to 0.996 for Unsegmented White Matter. However,
BPND measurements were remarkably stable (ranged 0.25% for
MCBP to 1.91% for CC_Mid_Posterior). Test-retest reproduc-
ibility of BPND assessed by ICC was excellent: the minimum ICC
was 0.970 for CC_Central; in several regions, including MCBP
and posterior cingulate cortex, test-retest ICC was 1.0.
III. Partial volume correction
Partial volume corrected binding potential values strongly
correlated with uncorrected values (Table 3). Thus, in most ROIs,
partial volume correction did not cause major changes in subject
ranking, as revealed by high values of Spearman correlation. Most
rank changes occurred in subjects with low levels of PiB uptake.
Lower Spearman correlations were observed in regions with low
PiB retention and narrow ranges of BPND values (e.g., hippocam-
pus).
IV. Regional specificity of PiB binding
Traditionally, PiB status has been determined by evaluating
MCBP, computed by averaging BPND over a fixed set of ROIs
[11,14,48]. For this purpose, our group has used four ROIs (see
Introduction) [10,11]. However, it is unclear whether the
determination of PiB status is sensitive to this particular choice.
To investigate this question, we evaluated regional BPND values in
relation to our measure of MCBP. In the majority of the cortical
regions, BPND values strongly correlated with the global MCBP
(Table 4, Fig. 3). As might be predicted, regions with high levels of
PiB binding in the clinically positive group (e.g., precuneus, BPND
= 0.73860.286 (mean 6 SD) and rostral anterior cingulate,
BPND= 0.65760.295) (Fig. 4) showed the greatest correlation with
MCBP (Pearson r = 0.98 and 0.96, respectively). Similarly,
subcortical structures with high levels of PiB binding in the
clinically positive group were also strongly correlated with MCBP,
e.g., caudate (r = 0.853), putamen (r = 0.862), and accumbens
(r = 0.913) (Table 5). Conversely, regions with lower BPND, e.g.,
the cuneus gyrus and the entorhinal cortex, more weakly
correlated with MCBP (Fig. 3). These lower correlations may
reflect a different trajectory of amyloid accumulation over time in
high vs. low BPND regions.
As noted earlier, previous studies have classified individuals as
PiB- vs. PiB+ using MCBP .0.18 as the criterion [11,44,45]. We
observed that many regions can be similarly used to classify
individuals, provided an appropriate ROI-specific criterion is
identified (Table 6). Among the FreeSurfer regions we examined,
26 cortical regions and 3 subcortical regions could be used to
determine PiB positivity with less than 10% difference in
classification using MCBP .0.18 as the reference. Identical




The main objective of this study was to examine the feasibility of
using FreeSurfer-defined ROIs in place of manual regions for
purposes of determining PiB status. A high level of agreement was
found between the manual and FreeSurfer-based approaches to
quantifying global amyloid burden using the MCBP. Moreoever,
we observed high test-retest ICC for BPND measurements using
FreeSurfer segmentations of repeated MRI scans. In fact, this ICC
(.0.970) is better than the reported ICC values for inter-rater
reliability and manual vs. automated comparison of regional PiB
uptake measurements [22]. This indicates the FreeSurfer based
PiB quantification is reliable in many regions and can therefore be
routinely deployed. Some regions, e.g., the frontal pole, exhibit
variable FreeSurfer volumes (test-retest ICC =0.684 in our data)
[27]. Nevertheless, measured BPND was generally reliable, even in
such regions (frontal pole ICC =0.995 in our data). It should be
pointed out that the BPND test-retest reproducibility in this study
only represents uncertainty attributable to region definition; we
did not conduct a full test-retest study with repeated PiB scans as
Table 6. List of regions that have less than 10% difference in
classifications for PiB positivity, and their corresponding BPND
threshold, number of difference in classifications (NOD), and
percentage difference in classification.
ROI Threshold NOD D%
Caudate 0.173 4 5.19
Putamen 0.363 5 6.49
Accumbens-area 0.227 3 3.90
ctx-bankssts 0.373 6 7.79
ctx-caudalanteriorcingulate 0.265 4 5.19
ctx-caudalmiddlefrontal 0.170 2 2.60
ctx-inferiorparietal 0.170 5 6.49
ctx-inferiortemporal 0.159 7 9.09
ctx-isthmuscingulate 0.255 6 7.79
ctx-lateralorbitofrontal 0.177 2 2.60
ctx-medialorbitofrontal 0.224 0 0.00
ctx-middletemporal 0.137 4 5.19
ctx-paracentral 0.208 7 9.09
ctx-parsopercularis 0.172 3 3.90
ctx-parsorbitalis 0.146 0 0.00
ctx-parstriangularis 0.224 1 1.30
ctx-postcentral 0.050 7 9.09
ctx-posteriorcingulate 0.279 2 2.60
ctx-precentral 0.125 6 7.79
ctx-precuneus 0.303 3 3.90
ctx-rostralanteriorcingulate 0.278 2 2.60
ctx-rostralmiddlefrontal 0.174 0 0.00
ctx-superiorfrontal 0.171 3 3.90
ctx-superiorparietal 0.129 4 5.19
ctx-superiortemporal 0.145 6 7.79
ctx-supramarginal 0.142 4 5.19
ctx-frontalpole 0.023 2 2.60
ctx-transversetemporal 0.232 6 7.79
ctx-insula 0.133 4 5.19
GR_FS 0.202 0 0.00
TEMP_FS 0.136 4 5.19
PREF_FS 0.154 2 2.60
doi:10.1371/journal.pone.0073377.t006
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done by Lopresti and colleagues [16]. Uncertainty in BPND (,1%
for most regions) attributable to FreeSurfer ROI definition
variability is only a small fraction of the full test-retest variability
reported by Lopresti et al. (,5%) [16].
This study confirms the observation that amyloid deposition
varies spatially [11,15]. Traditionally, a small number of regions
with the greatest PiB binding potentials have been used to evaluate
PiB status. However, we find that many regions are comparably
useful in determining PiB status, albeit with different thresholds
(Table 6). This observation reflects the high correlation of regional
BPND to MCBP in many regions (Table 4). The logic here is
reminiscent of the demonstration by Haxby and colleagues that
classification can be based on less robust features of imaging data
[49], Thus, it is not critical to identify the ‘‘optimal’’ set of regions
for determination of PiB status. Rather, we should focus on
developing a standard approach to facilitate multi-institutional
studies and cross comparisons of results from various groups.
It has not been standard practice in our group to apply partial
volume correction in PiB studies. The two-component partial
volume correction technique adopted by many groups [17,22]
compensates for the brain atrophy without modeling difference
between gray vs. white matter. In a comparison study [50], it was
demonstrated that three-component partial volume correction,
which differentiates between gray vs. white matter, provides a
more accurate estimation of regional intensity values. However,
the three-component model was more sensitive to errors in image
co-registration and segmentation. Therefore, it is not surprising
that two-component partial volume correction did not change the
rank of the amyloid burden measured by PiB PET, nor did it
change correlation to MCBP within individual cortical regions.
High correlations between cortical gray matter regions and the
underlying white matter reflect the limited spatial resolution of
PET. More sophisticated partial volume correction may enable
detection of more localized variations in PiB retention. But these
techniques must be thoroughly investigated to determine the
impact of registration and segmentation errors.
Conclusion
FreeSurfer-based ROI analysis has the advantage of automated
segmentation, which greatly reduces labor costs and potentially
enables standardization across laboratories. In addition, since
FreeSurfer is widely used in AD research [29,30,51], a FreeSurfer-
based amyloid imaging analysis protocol would allow integration
of amyloid deposition measurements with cortical thickness,
volume and other anatomical measurements. Although some
degree of variability exists in the automated segmentation
procedure [26,28,52], and manual correction of FreeSurfer-
derived boundaries is sometimes necessary, especially in the
presence of atrophy, our MRI test-retest study demonstrated
excellent reliability of the FreeSurfer based estimation of regional
BPND despite variability of ROI volumes. Our data also suggest
that the majority of cerebral cortical regions accumulate amyloid
in parallel. Longitudinal studies investigating the rate of amyloid
accumulation both globally and regionally are ongoing in our
laboratory.
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